Cabazitaxel,183133-96-2

Cabazitaxel (CAS 183133‑96‑2) is a semi‑synthetic taxane chemotherapy agent supplied by Highpharm Medchem Co., Ltd. in China. The product is described as pharmaceutical‑grade with high purity, suitable for clinical use in oncology. It is indicated primarily for the treatment of metastatic castration‑resistant prostate cancer and other resistant tumours. The supplier states that the material complies with ISO and FDA safety standards.

The active ingredient is supplied as a white crystalline powder, the form typically used for sterile injectable formulations. Industry standards usually demand a purity of at least 98 % verified by HPLC according to USP methods, matching the supplier’s high‑purity claim. Packaging is reported as secure; a common arrangement is a sealed amber glass vial with desiccant to guard against light and moisture. Standard storage is 2‑8 °C, protected from light, and the product generally remains stable for 24 months under these conditions.

Primary customers include hospitals, oncology clinics and pharmaceutical manufacturers that formulate the drug for clinical trials or therapeutic use. Highpharm Medchem offers flexible minimum order quantities, allowing buyers to adjust volumes to their specific demand. Shipping can be arranged on FOB or CIF terms, and payment is accepted via letter of credit or telegraphic transfer. Prospective importers should request the full certificate of analysis and confirm any additional regulatory documentation before finalising the order.

Highpharm Medchem Co., Ltd. is located at Rm1201, Shijilongteng Building, No.269 Zhong Ningbo, 315000 China. The company is listed as an imported‑tier supplier with a harbour trust tier, indicating it is a verified source within the platform’s network. Its response metrics show a 0 % response rate and no recorded average response time, suggesting that direct communication may be required to obtain detailed quotations. The firm specialises in the manufacture and distribution of pharmaceutical intermediates and active pharmaceutical ingredients.

According to the listing, the company provides Cabazitaxel that meets ISO and FDA certifications, although the specific certificate numbers are not disclosed and should be requested. No additional corporate history, employee count or revenue figures are provided, so buyers should seek further validation of manufacturing capacity and quality management systems as part of due diligence.